PB 127

Drug Profile

PB 127

Alternative Names: CardioSphere; CARDIOsphere; PBC 127

Latest Information Update: 08 Jun 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator POINT Biomedical
  • Class Albumins; Contrast media; Polyesters
  • Mechanism of Action Ultrasonography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cardiomyopathies

Most Recent Events

  • 27 Feb 2006 The US FDA has accepted the NDA for PB 127 for review
  • 09 Jan 2006 Preregistration for Cardiomyopathy (diagnosis) in USA (unspecified route)
  • 04 Mar 2004 Data from a media release have been added to the adverse events and Heart Failure therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top